Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.43 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.43 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840143 | 0.87 | KEAP1 (0.49) | ALDH1A1HTR7HTR6LMNALRRK2 | |
| SCHEMBL17700696 | 0.81 | CCR5 (0.52) | CCR5ALDH1A1RAB9AUSP2LMNA | |
| SCHEMBL11890513 | 0.81 | CCR5 (0.56) | CCR5ALDH1A1RAB9AHTR7HTR6 | |
| SCHEMBL7121592 | 0.80 | LRRK2 (0.49) | CCR5ALDH1A1RAB9AUSP2LMNA | |
| SCHEMBL12293726 | 0.80 | CCR5 (0.47) | CCR5ALDH1A1RAB9AHTR7HTR6 | |
| SCHEMBL8166488 | 0.79 | CCR5 (0.58) | CCR5ALDH1A1RAB9AHTR7HTR6 | |
| SCHEMBL3915066 | 0.79 | CCR5 (0.60) | CCR5ALDH1A1RAB9AHTR7HTR6 | |
| SCHEMBL2167632 | 0.79 | KMT2A (0.47) | CCR5ALDH1A1RAB9AUSP2LMNA | |
| SCHEMBL1783943 | 0.79 | KMT2A (0.47) | CCR5ALDH1A1RAB9AUSP2LMNA | |
| SCHEMBL16294377 | 0.79 | PTGER1 (0.54) | CCR5ALDH1A1RAB9AUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124903-A1 | SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2011-05-26 | — | — | US | disclosed |
| US-20100217034-A1 | Process for the Preparation of Fesoterodine | ACTAVIS GROUP PTC EHF (IS) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217034-A1 | Process for the Preparation of Fesoterodine | ADRB3, FES, QDPR | CCR5 3033/4885ALDH1A1 2791/4885RAB9A 532/4885 |
| US-20110124903-A1 | SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES | FES, NISCH, RPS27A | CCR5 4613/4885ALDH1A1 1371/4885RAB9A 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.